journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/29325035/amplicon-based-next-generation-sequencing-of-plasma-cell-free-dna-for-detection-of-driver-and-resistance-mutations-in-advanced-non-small-cell-lung-cancer
#1
N Guibert, Y Hu, N Feeney, Y Kuang, V Plagnol, G Jones, K Howarth, J F Beeler, C P Paweletz, G R Oxnard
Background: Genomic analysis of plasma cell-free DNA is transforming lung cancer care, however available assays are limited by cost, turnaround time, and imperfect accuracy. Here we study amplicon-based plasma next-generation sequencing (NGS), rather than hybrid-capture-based plasma NGS, hypothesizing this would allow sensitive detection and monitoring of driver and resistance mutations in advanced non-small cell lung cancer (NSCLC). Methods: Plasma samples from patients with NSCLC and a known targetable genotype (EGFR, ALK/ROS1 and other rare genotypes) were collected while on therapy and analyzed, blinded to tumor genotype...
January 9, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29324970/watson-for-oncology-and-breast-cancer-treatment-recommendations-agreement-with-an-expert-multidisciplinary-tumor-board
#2
S P Somashekhar, M-J Sepúlveda, S Puglielli, A D Norden, E H Shortliffe, C Rohit Kumar, A Rauthan, N Arun Kumar, P Patil, K Rhee, Y Ramya
Background: Breast cancer oncologists are challenged to personalize care with rapidly changing scientific evidence, drug approvals, and treatment guidelines. Artificial intelligence (AI) clinical decision-support systems (CDSSs) have the potential to help address this challenge. We report here the results of examining the level of agreement (concordance) between treatment recommendations made by the AI CDSS Watson for Oncology (WFO) and a multidisciplinary tumor board for breast cancer...
January 9, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29324995/pd-1-blockade-with-nivolumab-in-endemic-kaposi-sarcoma
#3
J Delyon, A Bizot, M Battistella, I Madelaine, L Vercellino, C Lebbé
No abstract text is available yet for this article.
January 8, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29324981/outcome-in-colorectal-cancer-tumour-stroma-and-so-much-more
#4
J H Park, D C McMillan
No abstract text is available yet for this article.
January 8, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29324972/prognostic-and-predictive-role-of-neutrophil-lymphocytes-ratio-in-metastatic-colorectal-cancer-a-retrospective-analysis-of-the-tribe-study-by-gono
#5
E Dell'Aquila, C Cremolini, T Zeppola, S Lonardi, F Bergamo, G Masi, M Stellato, F Marmorino, M Schirripa, F Urbano, M Ronzoni, G Tomasello, A Zaniboni, P Racca, A Buonadonna, G Allegrini, E Fea, S Di Donato, S Chiara, G Tonini, D Tomcikova, L Boni, A Falcone, D Santini
Background: Neutrophil/Lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial. Patients and Methods: Pts enrolled in TRIBE trial were included...
January 8, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29324969/apobec-mutagenesis-in-drug-resistance-and-immune-escape-in-hiv-and-cancer-evolution
#6
S Venkatesan, R Rosenthal, N Kanu, N McGranahan, J Bartek, S A Quezada, J Hare, R S Harris, C Swanton
The APOBEC mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants...
January 8, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29300831/incidence-and-management-of-diarrhea-in-patients-with-her2-positive-breast-cancer-treated-with-pertuzumab
#7
S M Swain, A Schneeweiss, L Gianni, J J Gao, A Stein, M Waldron-Lynch, S Heeson, M S Beattie, B Yoo, J Cortes, J Baselga
No abstract text is available yet for this article.
January 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29300805/targeting-the-fibroblast-growth-factor-receptor-2-in-gastric-cancer-promise-or-pitfall
#8
C Hierro, M Alsina, M Sánchez, V Serra, J Rodon, J Tabernero
No abstract text is available yet for this article.
January 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29300804/a-phase-ii-study-of-temsirolimus-added-to-low-dose-weekly-carboplatin-and-paclitaxel-for-patients-with-recurrent-and-or-metastatic-r-m-head-and-neck-squamous-cell-carcinoma-hnscc
#9
L A Dunn, M G Fury, H Xiao, S S Baxi, E J Sherman, S Korte, C Pfister, S Haque, N Katabi, A L Ho, D G Pfister
No abstract text is available yet for this article.
January 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29300815/inhibited-trapped-or-adducted-the-optimal-selective-synthetic-lethal-mix-for-brcaness
#10
Andrew Tutt
No abstract text is available yet for this article.
December 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29300814/body-mass-index-and-20-specific-cancers-re-analyses-of-dose-response-meta-analyses-of-observational-studies
#11
E K Choi, H B Park, K H Lee, J H Park, M Eisenhut, H J van der Vliet, G Kim, J I Shin
Background: Objectives were to provide an overview and understand the strength of evidence and extent of potential biases and validity of claimed associations between Body Mass Index (BMI) and risk of developing cancer. Methods: We performed an umbrella review and comprehensively re-analysed the data of dose-response meta-analyses on associations between BMI and risk of 20-specific cancers (bladder, brain, breast, colonic, rectal, endometrial, gallbladder, gastric, leukemia, liver, lung, melanoma, multiple myeloma, non-Hodgkins lymphoma, oesophagus, ovarian, pancreatic, prostate, renal, thyroid) by adding big data or missed individual studies...
December 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29300807/immune-related-adverse-events-of-immune-checkpoint-inhibitors-and-the-impact-of-sex-what-we-know-and-what-we-need-to-learne
#12
B C Özdemir, G Coukos, A D Wagner
No abstract text is available yet for this article.
December 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29293897/aromatase-inhibitors-and-the-risk-of-colorectal-cancer-in-post-menopausal-women-with-breast-cancer
#13
F Khosrow-Khavar, H Yin, A Barkun, N Bouganim, L Azoulay
Background: A large trial of post-menopausal women with breast cancer reported an imbalance in colorectal cancer events with aromatase inhibitors (AIs), compared with tamoxifen in the adjuvant setting. This unexpected signal was observed within 3 years of randomization. To date, no observational studies have examined this important safety question in the natural setting of clinical practice. Thus, the objective of this study was to determine whether AIs, when compared with tamoxifen, are associated with increased risk of colorectal cancer in post-menopausal women with breast cancer...
December 27, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29293881/prognostic-markers-for-colorectal-cancer-estimating-ploidy-and-stroma
#14
H E Danielsen, T S Hveem, E Domingo, M Pradhan, A Kleppe, R A Syvertsen, I Kostolomov, J A Nesheim, H A Askautrud, A Nesbakken, R A Lothe, A Svindland, N Shepherd, M Novelli, E Johnstone, I Tomlinson, R Kerr, D J Kerr
Background: We report here the prognostic value of ploidy and digital tumour-stromal morphometric analyses using material from 2624 patients with early stage CRC. Patients and Methods: DNA content (ploidy) and stroma-tumour fraction were estimated using automated digital imaging systems and DNA was extracted from sections of formalin-fixed paraffin-embedded (FFPE) tissue for analysis of microsatellite instability (MSI). Samples were available from 1092 patients recruited to the QUASAR 2 trial and two large observational series (Gloucester, n = 954; Oslo University Hospital, n = 578)...
December 27, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29293874/s-1-and-irinotecan-plus-bevacizumab-versus-mfolfox6-or-capeox-plus-bevacizumab-as-first-line-treatment-in-patients-with-metastatic-colorectal-cancer-tricolore-a-randomized-open-label-phase-3-non-inferiority-trial
#15
Y Yamada, T Denda, M Gamoh, I Iwanaga, S Yuki, H Shimodaira, M Nakamura, T Yamaguchi, H Ohori, K Kobayashi, M Tsuda, Y Kobayashi, Y Miyamoto, M Kotake, K Shimada, A Sato, S Morita, S Takahashi, Y Komatsu, C Ishioka
Background: Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment for metastatic colorectal cancer (mCRC). We performed a randomized, open-label, phase 3 trial to determine whether S-1 and irinotecan plus bevacizumab is non-inferior to mFOLFOX6 or CapeOX plus bevacizumab in terms of progression-free survival (PFS). Patients and methods: Patients from 53 institutions who had previously untreated mCRC were randomly assigned (1:1) to receive either mFOLFOX6 or CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group; a 3-week regimen: intravenous infusions of irinotecan 150 mg/m2 and bevacizumab 7...
December 27, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29293889/cns-response-to-osimertinib-in-patients-with-t790m-positive-advanced-nsclc-pooled-data-from-two-phase-ii-trials
#16
G Goss, C-M Tsai, F A Shepherd, M-J Ahn, L Bazhenova, L Crinò, F de Marinis, E Felip, A Morabito, R Hodge, M Cantarini, M Johnson, T Mitsudomi, P A Jänne, J C-H Yang
Background: Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic efficacy in patients with CNS metastases and early clinical evidence shows efficacy in the CNS. To evaluate osimertinib activity further, we present a pre-specified subgroup analysis of CNS response using pooled data from two Phase II studies: AURA extension (NCT01802632) and AURA2 (NCT02094261). Patients and methods: Patients with T790M-positive advanced NSCLC, who had progressed following prior epidermal growth factor receptor-tyrosine kinase inhibitor treatment, received osimertinib 80 mg once daily (n = 411)...
December 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29293878/safety-of-an-anti-pd-1-immune-checkpoint-inhibitor-in-a-liver-transplant-recipient
#17
P Biondani, E De Martin, D Samuel
No abstract text is available yet for this article.
December 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29293876/impact-of-homologous-recombination-deficiency-biomarkers-on-outcomes-in-patients-with-triple-negative-breast-cancer-treated-with-doxorubicin-based-adjuvant-chemotherapy-swog-s9313
#18
P Sharma, W E Barlow, A K Godwin, H Pathak, K Isakova, D Williams, K M Timms, A R Hartman, R J Wenstrup, H M Linden, D Tripathy, G N Hortobagyi, D F Hayes
Background: Homologous recombination deficiency (HRD) causing alterations have been reported in triple-negative breast cancer (TNBC). We hypothesized that TNBCs with HRD alterations might be more sensitive to anthracycline plus cyclophosphamide-based chemotherapy and report on HRD status and BRCA1 promoter methylation (PM) as prognostic markers in TNBC patients treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG9313. Patients and Methods: 425 TNBC patients were identified from S9313...
December 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29309540/radiotherapy-and-anti-pd-1-pd-l1-combinations-in-lung-cancer-building-better-translational-research-platforms
#19
T Kordbacheh, J Honeychurch, F Blackhall, C Faivre-Finn, T Illidge
Despite the unheralded success of immune checkpoint blockade in delivering durable responses for some patients with non-small cell lung cancer (NSCLC), the majority of patients do not respond. PD-L1 tumour expression and pre-existing tumour T-cell infiltration have been correlated with improved clinical outcomes to anti-PD-1/anti-PD-L1. However, patients with tumours that are negative for PD-L1 expression can also respond to treatment. Strategies to combine other treatment modalities like radiotherapy with immune checkpoint inhibitors are being investigated as means of improving the response rates to PD-1/PD-L1 antibody blockade...
December 22, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29272364/autologous-stem-cell-transplantation-after-second-line-brentuximab-vedotin-in-relapsed-or-refractory-hodgkin-lymphoma
#20
A F Herrera, J Palmer, P Martin, S Armenian, N-C Tsai, N Kennedy, F Sahebi, T Cao, L E Budde, M Mei, T Siddiqi, L Popplewell, S Rosen, L Kwak, A Nademanee, S Forman, R Chen
BACKGROUND: We previously demonstrated that brentuximab vedotin (BV) used as second-line therapy in patients with Hodgkin lymphoma is a tolerable and effective bridge to autologous hematopoietic cell transplantation (AHCT). Here we report the post-AHCT outcomes of patients treated with second-line standard/fixed-dose BV and an additional cohort of patients where positron-emission tomography (PET) adapted dose-escalation of second-line BV was utilized. PATIENTS AND METHODS: Patients on the dose-escalation cohort received 1...
December 20, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"